For most of its history, cystic fibrosis asked people to plan their lives around breath, weight, and survival, and parenthood was quietly placed beyond reach for many. Now that modulator drugs have begun to change what the body can do, the Cystic Fibrosis Foundation has offered its first full map of reproductive life, from the first conversations of adolescence through pregnancy and beyond. The guidance is a sign that a long-neglected dimension of living with the disease is finally being taken seriously, even as its open questions, especially for men, remain unanswered.
New CF Guidance Brings Reproductive Health Into Routine Care as Pregnancy Rates Rise
Women who once faced fertility challenges are beginning to conceive naturally
Mark
Why is this guidance a big deal? Haven't people with CF been having these conversations already?
Mimi
Not systematically. Reproductive health used to sit behind lung function and weight in the visit. This is the first clinical guidance covering it across a lifespan, with annual talks starting in the teen years.
Mark
What drove the change?
Mimi
Modulators. After Trikafta was approved in 2019 in the U.S. and 2020 in the U.K., pregnancy rates nearly doubled in both countries.
Luke
Nearly doubled is the author's description. And the cervical mucus explanation is hedged in the piece: modulators may help explain it. It's not proven as the cause.
Mark
So what should women who don't want pregnancy take from it?
Mimi
Don't assume CF is contraception. Most options are open to them, except that Orkambi can weaken hormonal methods.
Mark
And the newborn screening issue?
Mimi
It's an odd side effect of success. Babies exposed in utero may not show the usual signs, so screening could miss CF, and genetic testing after birth helps.
Luke
That rests on early research and case reports, not large trials. Same for the men: boys born with intact vas deferens after prenatal exposure is a handful of cases. Nobody knows yet if fertility holds up later.
Mark
Anything else unresolved?
Luke
Long-term effects of modulators on babies. The author calls current safety evidence reassuring, but says there's still much to learn.
O Pulso
- Pregnancy rates among women with CF nearly doubled in the U.S. and U.K. after Trikafta arrived, catching clinicians off guard.
- Providers who had never been trained for these questions now have to answer them, and the Foundation pulled in specialists from around the world to do it.
- Women with CF cannot assume the disease will prevent pregnancy, so contraception counseling is being pushed into the clinic, with one older modulator, Orkambi, threatening hormonal methods.
- Pregnancy still carries higher risk, so teams are pressing for preconception visits, carrier screening, glucose testing, and closer monitoring through pregnancy.
- Newborn screening may miss babies exposed to modulators in the womb, a gap that could delay diagnosis.
- For men, a few case reports of boys born with intact vas deferens hint at a possible shift, but without larger studies the outcome remains uncertain.
For most of its history, cystic fibrosis asked people to plan their lives around breath, weight, and survival, and parenthood was quietly placed beyond reach for many. Now that modulator drugs have begun to change what the body can do, the Cystic Fibrosis Foundation has offered its first full map of reproductive life, from the first conversations of adolescence through pregnancy and beyond. The guidance is a sign that a long-neglected dimension of living with the disease is finally being taken seriously, even as its open questions, especially for men, remain unanswered.
In August 2026, the Cystic Fibrosis Foundation published its first clinical guidance on reproductive health across the whole lifespan of a person with CF. It calls for age-appropriate education early on and a yearly conversation about reproductive health beginning in the teen years. The piece comes from the guidance's corresponding author, so it reads as an insider's account.
The need is recent. For much of CF's history, clinic visits focused on lungs, weight, and symptoms, and many patients grew up assuming biological parenthood was out of reach. The arrival of CFTR modulators, especially the triple-combination Trikafta approved in 2019 in the U.S. and 2020 in the U.K., changed that. Pregnancy rates in both countries nearly doubled, and some women conceived naturally, often to their surprise. Clinicians suddenly faced questions earlier generations rarely met, and the Foundation convened specialists from around the world to answer them.
For women who do not want pregnancy, the guidance is clear that CF offers no natural protection. Most modulators do not interfere with contraception, but Orkambi can make hormonal methods less effective, so patients are advised to choose a method with both a CF specialist and an Ob/Gyn. For those hoping to conceive, a preconception visit with the CF team can cover lung function, nutrition, diabetes risk, and medications, along with genetic counseling and carrier screening for patients and partners.
Pregnancy remains higher risk, with more premature births and gestational diabetes, so visits become more frequent and often include a maternal-fetal medicine specialist. Stopping an effective modulator can harm the patient's own health, so the author advises continuing it unless the care team says otherwise. Current safety evidence is reassuring, though long-term effects are still unknown. Breastfeeding is increasingly possible for well-nourished mothers, but modulators do pass into breast milk, so the decision should involve both the CF team and the pediatrician.
One newer complication is that babies exposed to modulators before birth may not show the usual newborn screening signs, which means standard screening could miss CF.
For men, more than 95% are born without vas deferens and cannot conceive naturally, though most still make sperm and can use retrieval with IVF. Modulators cannot create a missing vas deferens, yet several case reports describe boys exposed before birth who had intact ones. Those reports are not large studies, so whether prenatal exposure preserves fertility is still an open question worth watching.
In August 2026, the Cystic Fibrosis Foundation published something the field had never had: clinical guidance on reproductive health across the whole lifespan of a person with CF. It recommends age-appropriate education early on, and a conversation about reproductive health at least once a year beginning in the teen years. The piece describing it comes from the guidance's corresponding author, so it reads as an insider's account rather than an outside review.
The need for it is recent. For much of CF's history, clinic visits centered on lung function, weight, and whether symptoms were getting in the way of the day. Fertility problems were the norm for men and women with the disorder, and many grew up assuming biological parenthood was off the table.
CFTR modulators changed that. The first was introduced in 2012. The triple-combination drug elexacaftor/tezacaftor/ivacaftor, sold as Trikafta, was approved in the U.S. in 2019 and in the U.K. in 2020. After that, pregnancy rates in both countries nearly doubled. Some women who had expected fertility trouble conceived naturally, often to their surprise. The author notes that CF can thicken cervical mucus enough to block sperm from reaching the uterus, and that modulator therapy can improve that environment, which may help explain the shift. Clinicians suddenly faced questions earlier generations of CF providers rarely met, and the Foundation convened a multidisciplinary group of specialists from around the world to answer them.
One practical consequence is that women with CF who do not want to become pregnant should not assume the disease will protect them. Most have the same range of contraceptive options as anyone else. The exception is lumacaftor/ivacaftor (Orkambi), an older and less commonly used modulator that can make hormonal contraception less effective. Most other modulators do not interfere. Patients are advised to choose a method with a CF specialist and an Ob/Gyn.
For those who want to conceive, the guidance points to a visit with the CF team beforehand. That visit can address lung function, nutrition and weight, CF-related diabetes or the risk of it, medications and supplements, and other CF-related conditions. It is also the time for a genetic counselor and carrier screening, a blood test that estimates the chance a child could inherit CF or another genetic condition. Patients and partners should be offered it, ideally before pregnancy. Counselors can discuss prenatal testing or IVF with preimplantation genetic testing.
Pregnancy with CF is still considered higher risk, with elevated chances of premature birth and gestational diabetes. Patients need more frequent visits with CF and obstetric teams, likely including a maternal-fetal medicine specialist. Modulators and other CF drugs cross the placenta, but stopping an effective modulator can make the patient's own health decline, so the author advises not stopping unless the care team recommends it. Current safety evidence is reassuring, the author writes, though long-term effects remain unknown. UT Southwestern has taken part in research on whether CF medications are safe during pregnancy and breastfeeding and for babies in their first two years. About 30% to 40% of adults with CF develop CF-related diabetes, so the guidance recommends an oral glucose tolerance test before pregnancy and extra testing during it. Catching high blood sugar early allows treatment that can reduce risks such as high blood pressure in pregnancy, premature birth, and C-section delivery.
Breastfeeding is increasingly possible for women whose nutrition is solid going in. Modulators do pass into breast milk, so the decision should involve the CF team and the baby's pediatrician, with close attention to nutrition and weight after delivery.
A newer complication involves newborn screening. Early research and case reports suggest babies with CF exposed to modulators before birth may not show typical signs, such as high immunoreactive trypsinogen, severe jaundice, salty skin, or severe neonatal constipation. Standard screening may therefore miss CF, and genetic testing after birth can give a clearer answer when inheritance is possible.
For men, the picture is different. More than 95% of men with CF are born without vas deferens, the tubes that carry sperm, and cannot conceive naturally. Most still produce sperm, so those wanting biological children generally need sperm retrieval plus assisted reproduction such as IVF. Modulators cannot build a vas deferens that did not form, but several case reports describe boys exposed before birth who were born with intact ones. These are case reports, not large studies, so whether prenatal exposure preserves fertility is unknown. Larger studies are what to watch.
Citações Notáveis
Do not stop taking CF medications unless the care team recommends it.— Corresponding author of the CF Foundation reproductive health guidance
These are case reports, not large studies, so we cannot yet say whether prenatal exposure will preserve fertility later in life.— Corresponding author of the CF Foundation reproductive health guidance
Quer a matéria completa?
Leia o original em News-Medical ↗
Health & Medicine